Epitopea Secures $31 Million for Cancer Immunotherapy Development
Epitopea, a pioneering company in the field of cancer immunotherapeutics, has successfully raised a significant amount of USD $31 million in Pre-Series A funding. This funding round attracted a diverse set of backers, including notable investors such as Investissement Québec, adMare BioInnovations, and Jonathan Milner. Other esteemed backers include existing investors like Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarité FTQ, the Harrington Discovery Institute, IRICoR, and Novateur Ventures. This substantial financial boost marks a crucial step for the company as it aims to further its strategic development and enter clinical stages with its lead Cryptigen immunotherapeutics.
Founded in 2021, Epitopea is led by the visionary CEO Dr.
Alan C. Rigby and operates from two significant locations: Cambridge in the United Kingdom and Montreal in Canada. The company is dedicated to creating accessible, off-the-shelf RNA-based immunotherapies targeting hard-to-treat cancers. These innovative therapies leverage a new class of untapped tumor-specific antigens, known as CryptigenTM TSAs, which are characterized by their broad presence across multiple patients with the same cancer type. Epitopea's proprietary CryptoMapTM platform facilitates the creation of an extensive library of novel CryptigenTM TSAs by utilizing advanced techniques in immunopeptidomics, genomics, and bioinformatics. This strategic approach enables the identification of aberrantly-expressed tumor-specific antigens (aeTSA’s) concealed within cancer’s 'junk' DNA.
The discovery of these hidden CryptigenTM TSAs can be traced back to cutting-edge research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer, which is situated at the Université de Montréal. The innovative efforts of these researchers have laid a robust foundation for the advancements that Epitopea is now poised to achieve in the field of cancer treatment. With more than USD $45 million raised to date, the company is well-equipped to make significant strides toward changing the landscape of cancer therapy and improving patient outcomes through its groundbreaking immunotherapeutic solutions.
They've invested in Epitopea
Get to know these Biotech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Investissement Québec | investment(s) investment(s) | more info | |||
2 |  adMare BioInnovations | investment(s) investment(s) | more info | |||
3 |  Advent Life Sciences | 3 investment(s) investment(s) | 10 contacts contacts | |||
4 |  CTI Life Sciences | investment(s) investment(s) | more info | |||
5 |  Cambridge Innovation Capital | 7 investment(s) investment(s) | 10 contacts contacts | |||
6 |  Fonds de Solidarité FTQ | investment(s) investment(s) | more info | |||
7 |  the Harrington Discovery Institute | investment(s) investment(s) | more info | |||
8 |  IRICoR | investment(s) investment(s) | more info | |||
9 |  Novateur Ventures | 1 investment(s) investment(s) | more info |
Click here for a full list of 6,481+ startup investors in the UK